Circulating bronchoepithelial cells expressing mRNA for surfactant protein A in patients with pulmonary fibrosis  by DOHMOTO, K. et al.
Circulating bronchoepithelial cells expressing
mRNA for surfactant protein A in patients
with pulmonary fibrosis
K. DOHMOTO*, S. HOJO*, J. FUJITA*, T. KAMEI{, Y. UEDA*, H. MIYAWAKI{, S. BANDOH*,
H. OKADA* AND J. TAKAHARA*
*First Department of Internal Medicine, Kagawa Medical University, Kagawa, {Department of Internal
Medicine, Kagawa Prefectural Central Hospital, Kagawa and {Department of Internal Medicine, Ritsurin
Hospital, Kagawa, Japan
There are several unsolved clinical findings in patients with idiopathic pulmonary fibrosis (IPF); (i) predominance
of fibrosis in the lower lung fields, (ii) digital clubbing, and (iii) patchy distribution of pulmonary fibrosis. To
explain these unsolved problems, we hypothesized that regenerated or premature bronchoepithelial cells may
circulate in the blood in patients with IPF. To prove this, we performed the reverse transcriptase-polymerase chain
reaction (RT-PCR) for cytokeratin 19 (CK19) and pulmonary surfactant protein A (SPA) in peripheral blood in
patients with IPF and pulmonary fibrosis associated with collagen vascular disorders. In addition, 20 patients with
chronic pulmonary emphysema as a disease control and 19 normal volunteers were also evaluated for the existence
of circulating bronchoepithelial cells.
RT-PCR analysis showed that CK19 was expressed in 12 of 38 blood samples (316%) of IPF and pulmonary
fibrosis associated with collagen vascular disorders, seven of 20 (350%) blood samples of chronic pulmonary
emphysema, and four of 19 (211%) blood samples of normal volunteers. mRNA for SPA was positive in eight of
38 (211%) blood samples of IPF. In contrast, SPA expressing cells were not detected in any blood samples
obtained from patients with chronic pulmonary emphysema or normal volunteers.
This evidence suggests that there were some circulating bronchoepithelial cells expressing mRNA for SPA in
peripheral blood of patients with IPF and pulmonary fibrosis associated with collagen vascular disorders.
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Idiopathic pulmonary fibrosis (IPF) is an inflammatory
lung disease which is characterized by the accumulation of
inflammatory cells and deposition of collagen resulting in
lung remodelling. It has been reported that lung cancer is
frequently associated with IPF and the prevalence of lung
cancer in patients with IPF has been reported to be more
than 30% (1). Carcinogenesis is believed to involve multi-
step genetic mutations, and several gene mutations have
been found in hyperplastic, metaplastic and dysplastic
epithelium (2). Recently, we and other investigators haveReceived 18 August 1999 and accepted in revised from 25
November 1999.
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0954-6111/00/050475+07 $35?00/0demonstrated overexpression of p53 proteins in broncho-
epithelial cells by immunostaining (3), suggesting that
bronchoepithelial cells have some DNA damage. In
addition, we also have reported that heterogeneous point
mutations of p53 genes are observed in lung specimens in
patients with pulmonary fibrosis (4).
There are several unsolved clinical findings in patients
with IPF; (i) predominance of fibrosis in the lower lung
fields, (ii) digital clubbing, and (iii) the patchy distribution
of pulmonary fibrosis. To explain these unsolved problems,
we hypothesized that regenerated or premature bronchoe-
pithelial cells may circulate in the blood in patients with
pulmonary fibrosis. If there are circulating bronchoepithe-
lial cells able to release several cytokines and cause fibrosis,
predominance of fibrosis in the lower lung fields as well as
the patchy distribution of pulmonary fibrosis may be
explained. If these circulating bronchoepithelial cells are
trapped at the digits and release several growth factors,
pathogenesis of digital clubbing may be explained. We
therefore tested for the existence of the RNA which encodes# 2000 HARCOURT PUBLISHERS LTD
476 K. DOHMOTO ET AL.the intermediate filament protein cytokeratin 19 (CK19)
and surfactant protein A (SP-A) as a marker for
bronchoepithelial cells in patients with IPF as well as
patients with pulmonary fibrosis associated with collagen
vascular disorders and compared them to patients with




Thirty-eight patients (aged between 34 to 81 years, median
age 675, 12 females and 26 males) with pulmonary fibrosis
(IPF and pulmonary fibrosis associated with collagen
vascular disorders), and 20 patients with chronic pulmon-
ary emphysema (aged between 55 to 84 years, median age
765, 1 female and 19 males) were entered in this study
(Table 1). Twenty-five of 38 patients (658%) with
pulmonary fibrosis, and all of chronic pulmonary emphy-
sema patients were smokers. Eight patients were diagnosed
to have pulmonary fibrosis associated with collagen
vascular disorders [progressive systemic sclerosis (two),
polymyositis/dermatomyositis (two), Sjo¨gren syndrome
(one) rheumatoid arthritis (two), and systemic lupus
erythematosus (one)], and 20 patients were diagnosed to
have IPF. Patients were diagnosed as having pulmonary
fibrosis by Raghu’s criteria (5). In addition, high-resolution
computed tomography was performed in all patients, and
diagnoses of pulmonary fibrosis as well as chronic
pulmonary emphysema were confirmed by two expert
radiologists. High-resolution computed tomography find-
ings also demonstrated that there was no evidence of
complicated lung cancer in any of the patients with
pulmonary fibrosis. Histological confirmation was obtained
by open lung biopsy (N8) or transbronchial lung biopsy
(N30). All patients with pulmonary fibrosis were diag-
nosed to be compatible with the usual interstitial pneumo-
nia, histologically. All patients with pulmonary fibrosis
associated with collagen vascular disorders had been
treated with steroid hormone.
Nineteen age-matched normal volunteers (aged between
30 to 77 years, median age 66, seven females and 12 males)
were also evaluated. Seven of them were smokers.
MONONUCLEAR CELL ISOLATION AND
RNA EXTRACTION
Peripheral venous blood samples (10 ml) were obtained
with a standard venepuncture technique using a heparinized
tube. Mononuclear cells from peripheral blood samples
were isolated using a Ficoll gradient as described previously
(6,7). A well-characterized human adenocarcinoma cell line,
PC3 was used in this study as the positive control. Total
RNA was extracted by the Guanidinium thiocyanate
phenol-chloroform method using a commercial RNA
preparation kit (RNAsolTM B;TEL-TEST, INC., Friends-
wood, TX). The extracted RNA was dissolved in RNase-free water to 10 mg/ml and stored at 7808C. The quantity
and quality of the RNA preparations were determined by
absorbance at 260 nm and 280 nm.
REVERSE TRANSCRIPTASE-POLYMERASE
CHAIN REACTION (RT-PCR)
Reverse transcriptase (RT) reaction was prepared in a final
volume of 20 ml and contained 10 mg of total RNA, 1 ml of
1 pmol/ml Oligo dT and 1 ml of RT enzyme (SUPER-
SCRIPTTMII RNase H7 Reverse Transcriptase (RT;GIB-
CO BRL, Gaithersburg, MD). PCR reaction was
performed in a final volume of 50 ml, contained reaction
buer, dNTP (025 mM of each), Taq DNA polymerase
[TaKaRa Z Taq (the first step of PCR for CK19) and
TaKaRa g Taq (the second step of PCR for CK19),
TaKaRa, Tokyo, Japan], 20 pmol of each primer, 1 ml of
cDNA, and 3725 ml of H2O. CK19-specific oligonucleotide
primers used for the first step of PCR (A: 5’-AAGCTAAC-
CATGCAGAACCTCAACGACCGC-3’ and B: 5’-
TTATTGGCAGGTCAGGAGAAGAGCC-3’) were
synthesized as reported previously by Datta et al. (8).
Primers used for the second step of PCR (S: 5’-AGGTG-
GATTCCGCTCCGGGCA-3’ and D: 5’-CGCGACTT-
GATGTCCATGAGCCGCTGGTAC-3’) were synthesized
as reported previously by Datta et al. (8) and Bostick et al.
(9). The cycling conditions of the PCR for CK19 were as
follows; 948C for 1 min, 688C for 2 min, for 15 cycles for the
first PCR and 35 cycles for the second PCR. The first PCR
product was a 1069 bp fragment and the second PCR
product was a 409 bp fragment.
SPA-specific oligonucleotide primers were as follows; S:
5’-GAAGGACGTTTGTGTTGGAA-3’ and AS: 5’-
TGGATTCCTTGGGACAGCAA-3’ (10). The cycling
conditions of the PCR for SPA was as follows; 948C for
1 min, 548C for 15 min, 728C for 2 min, for 45 cycles. The
PCR product generated a 439 bp fragment.
Integrity of RNA and adequate cDNA synthesis was
confirmed by determining the presence of glyceraldehyde
phosphate dehydrogenase (GAPDH) mRNA in the same
sample, using primers 5’-GTCAACGGATTTGGTCTG-
TATT-3’ and 5’-AGTCTTCTGGGTGGCAGTGAT-3’ as
reported previously (11). The cycling conditions were as
follows; 948C for 1 min, 568C for 2 min, and 728C for 2
min, for 20 cycles.
All PCR reactions were preceded by a denaturation step
at 948C for 3 min, and were terminated by a 10 min
extension at 728C. These PCR were performed in a
thermocycler (SANTHERMOPCR; Sanko Junyaku Co.,
Ltd., Tokyo, Japan).
PCR amplification products were electrophoretically
separated on 2% agarose gel and visualized by ethidium
bromide staining. In addition, nucleotide sequences of
amplified products were sequenced. Sequence analysis was
performed using an ABI PRISM 377 DNA Sequencer
(ABI, Foster City, CA) with BigDye Terminator Cycle
Sequencing Ready Reaction (ABI, Foster City, CA), and
confirmed that the amplified products were identical to the
expected sequences of cDNA of CK19 as well as SPA.















1 73M IPF No No Smoker 738 () ()
2 59M IPF No No Smoker NE () (7)
3 70M IPF Yes No Smoker 242 () (7)
4 55F IPF Yes No Non-smoker 342 () ()
5 60M PSS No No Smoker 369 () (7)
6 72M IPF No No Smoker 246 () (7)
7 59F IPF No No Non-smoker 852 () (7)
8 64M IPF No No Smoker 832 () (7)
9 48M IPF No Yes(wood) Smoker NE (7) ()
10 77F IPF No No Non-smoker NE (7) ()
11 69M IPF No Yes(metal) Non-smoker NE (7) (7)
12 62F DM No No Non-smoker 345 (7) (7)
13 58M IPF Yes Yes(gas) Smoker 433 (7) (7)
14 57M IPF No No Smoker NE (7) (7)
15 65M IPF Yes Yes(wood) Smoker 263 (7) (7)
16 81M IPF No No Smoker 195 (7) (7)
17 66M IPF Yes No Smoker 275 (7) (7)
18 73M IPF No No Smoker 527 (7) (7)
19 61M IPF Yes No Smoker 163 (7) ()
20 34M PSS No No Smoker NE (7) (7)
21 69F Sjo¨gren No No Non-smoker 433 () (7)
22 74F IPF No No Non-smoker 317 (7) (7)
23 73F RA No No Non-smoker 215 (7) (7)
24 61M IPF Yes No Smoker NE (7) (7)
25 84M IPF No No Smoker 336 (7) (7)
26 59F IPF No No Non-smoker NE (7) (7)
27 65F IPF No No Non-smoker NE (7) (7)
28 70M IPF No Yes(metal) Smoker NE (7) (7)
29 79F Sjo¨gren No No Non-smoker 832 (7) (7)
30 60M IPF No No Smoker 151 () (7)
31 78M IPF No Yes(wood) Smoker 531 () (7)
32 71M IPF No No Smoker NE (7) ()
33 71M IPF No No Smoker 190 (7) ()
34 71M IPF No No Smoker 193 (7) ()
35 56F SLE No No Non-smoker 303 (7) (7)
36 58F DM No No Non-smoker 302 () (7)
37 72M IPF No No Smoker NE (7) (7)
38 73M IPF No Yes(metal) Smoker 530 (7) (7)
39 80F CPE No No Smoker NE (7) (7)
40 55M CPE No No Smoker NE (7) (7)
41 75M CPE No No Smoker 144 (7) (7)
42 79M CPE No No Smoker 181 (7) (7)
43 81M CPE Yes No Smoker 244 (7) (7)
44 65M CPE No No Smoker 250 (7) (7)
45 81M CPE No No Smoker 173 () (7)
46 76M CPE No Yes(wood) Smoker 209 () (7)
47 79M CPE Yes No Smoker 187 (7) (7)
48 71M CPE No No Smoker 177 (7) (7)
49 68M CPE No No Smoker 183 (7) (7)
50 65M CPE No No Smoker 214 (7) (7)
51 62M CPE No No Smoker 175 (7) (7)
52 73M CPE No No Smoker NE (7) (7)
53 84M CPE No No Smoker 212 (7) (7)
















54 69M CPE Yes No Smoker 181 () (7)
55 78M CPE No No Smoker NE () (7)
56 84M CPE No Yes(wood) Smoker 214 () (7)
57 61M CPE No No Smoker 211 () (7)
58 77M CPE No No Smoker 233 () (7)
IPF: idiopathic pulmonary fibrosis; CPE: chronic pulmonary emphysema; PSS: scleroderma; RA: rheumatoid arthritis; DM:
dematomyositis; SLE: systemic lupus erytematosus; Sjo¨gren: sjo¨gren syndrome; NE: not evaluated; CK19: cytokeratin
19; SPA: surfactant protein A
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By RT-PCR analysis for GAPDH, mRNA for GAPDH
was detected in all samples (data not shown).
By RT-PCR analysis for CK19, amplified products of
409 bp were clearly demonstrated (Fig. 1). The size of
amplified products from blood samples were the same as
that of PC3 (PLATE 1). Amplified products were demon-
strated in 12 of 38 blood samples (316%) of patients with
pulmonary fibrosis, seven of 20 blood samples (350%) in
chronic pulmonary emphysema, and four of 19 samples
(211%) of normal volunteers (Fig. 1, Table 2). In addition,
the quantity of CK19 mRNA for PC3 (per 1 mg/1 ml total
RNA) is about 106 to 107 times higher than that of
peripheral blood samples (data not shown). Sequence
analysis demonstrated that all these amplified products
were part of cDNA of CK19.FIG. 1. Expression of CK19 mRNA in the peripheral
blood. The amplified products of CK19 (409 bp) is
indicated. Lane 1 and 7: positive control (PC3), lanes 2–6:
patients with pulmonary fibrosis, lanes 8–12: patients with
pulmonary emphysema, and lane M: molecular weight
standard ( x174 Hae III digest).By RT-PCR analysis for SPA, amplified products of 439
bp were clearly demonstrated, and the size of amplified
products from blood samples were the same as that of PC3
(Fig. 2). Amplified products were demonstrated in eight of
38 (211%) blood samples of IPF (Table 2). In contrast,
SPA mRNA were not detected in any blood samples
obtained from patients with chronic pulmonary emphyse-
ma or normal volunteers (Table 2). In addition, the
quantity of SPA mRNA for PC3 (per 1 mg/1 ml total
RNA) was about 106 to 107 times higher than that of
peripheral blood samples (data not shown). Sequence
analysis demonstrated that all these amplified products
were part of cDNA for SPA. The number of patients who
expressed mRNA of SPA was 8. However, seven of those
eight did not express mRNA of CK19 (Table 2).
There was no relationship between the existence of
clubbed finger and expression of mRNA for CK19 or
expression of mRNA for SPA (Table 1).
Discussion
In the past several years, the possibility of using RT-PCR
analysis to detect micrometastatic cancer cells has received
increasing attention (8–10, 12–16). A variety of genes (for
example cytokeratin 8, CK19, cytokeratin 20, carcinoem-
bryonic antigen, MUC 1, and SPA) have been evaluated for
their ability to act as markers of malignant cells in the
lymph nodes, bone marrow, and blood of patients with
cancer (9,10).
Among these varieties of genes, the most extensively
studied gene is CK19, and it has been shown to be widely
expressed in breast, colon, small and non-small cell lung,
and prostate cancer cells (16,17). Therefore, we attempted
to detect the CK19 mRNA in serum from patients with
IPF.
In this report, we carefully assessed the presence of
illegitimate CK19 transcripts. In 1999, Ruud et al. (18) have
reported a novel pseudogene. Therefore, we used new
primer sets for nested PCR to avoid the amplification of
two known pseudogenes of CK19 (18,19).









IPF and PF-CVD (N38) 1/38 (26%) 11/38 (289%) 7/38 (184%) 19/38 (500%)
CPE(N20) 0/20 (0%) 7/20 (350%) 0/20 (0%) 13/20 (650%)
Control (N19) 0/19 (0%) 4/19 (211%) 0/19 (0%) 15/19 (789%)
IPF: idiopathic pulmonary fibrosis; PF-CVD: pulmonary fibrosis associated with collagen vascular disorders; CPE: chronic
pulmonary emphysema; Control: healthy volunteer. The percentages are shown in brackets.
CIRCULATING BRONCHOEPITHELIAL CELLS IN IPF 479In our study, RT-PCR analysis showed that CK19 was
expressed in 12 of 38 blood samples (316%) in pulmonary
fibrosis, seven of 20 blood samples (350%) in chronic
pulmonary emphysema, and four of 19 blood samples
(211%) in normal volunteers. There are conflicts concern-
ing the usefulness of CK19 mRNA to detect circulating
cancer cells. Several reports have described that low levels
of CK19 are detected in non-epithelial tissues such as
endothelial cells and fibroblasts (6,9,15,16,20,21). Recently,
Bustin et al. have reported mRNA for CK19 is expressed in
30% of blood samples taken from healthy volunteers (22)
as observed in our study. We concluded that it was
unsuitable to use CK19 mRNA to detect circulating
bronchoepithelial cells, even if the amplification of CK19
pseudogenes was avoided.
Pulmonary surfactant plays an important role in low-
ering the surface tension in the alveoli and therefore
prevents lung collapse at low lung volumes. Surfactant is
a lipoprotein complex and consists primarily of lipids
(90%) and 5–10% proteins. Surfactant proteins (SP) 7A,
7B,7C, and7D are synthesized and secreted by alveolar
type II cells or bronchiolar Clara cells (23–27). It has been
reported that SPA is a lung-specific protein (28,29). SaitohFIG. 2. Expression of SPA mRNA in the peripheral blood.
The amplified products of SPA (439 bp) is indicated. Lane
1: positive control (PC3), lanes 2–9; patients with
pulmonary fibrosis, and lane M: molecular weight
standard ( x174 Hae III digest).et al. (10) have reported that RT-PCR of the SPA gene
transcript in pleural eusion is useful for the diagnosis of
primary lung adenocarcinoma. In addition, Betz et al. (24)
have reported that the SPA gene is detected in metastatic
and micrometastatic pulmonary adenocarcinomas by using
RT-PCR from paratracheal and subcarinal lymph nodes.
Although there are few reports that have described the RT-
PCR for SPA, it is confirmed that SPA is useful for the
diagnosis of primary lung adenocarcinoma.
Importantly, in the present study, RT-PCR analysis
showed that SPA was expressed in eight of 38 blood
samples (211%) in patients with pulmonary fibrosis. In
contrast, SPA-expressing cells were not detected in patients
with chronic pulmonary emphysema or normal volunteers.
In addition, seven of those eight did not express mRNA of
CK19. Since SPA is a lung-specific protein, this discrepancy
suggested that the expression of mRNA of CK19 may not
have reflected the circulating bronchoepithelial cells. How-
ever, our present study strongly suggests that there were
some circulating bronchoalveolar cells expressing mRNA
of SPA in the peripheral blood of patients with pulmonary
fibrosis. There are some reports which have described the
presence of non-neoplastic epithelial cells in peripheral
blood. Castells et al. have described that inflammatory
bowel disease has detectable CEA mRNA expression in the
blood. This evidence indicates the presence of non-
neoplastic epithelial colonic cells in blood (30). In addition,
Hillaire et al. have also reported detectable mRNA for
albumin in the blood obtained from patients with hepatitis
that suggests the presence of normal hepatocytes in the
blood (31). From these reports, it might be reasonable to
speculate that some bronchoepithelial cells are present in
the blood of patients with pulmonary fibrosis.
The clinical significance of the existence of SPA expres-
sing bronchoepithelial cells in blood should be discussed.
Based on results of RT-PCR for SPA, we speculated that
some circulating bronchoepithelial cells may play a role in
the repair of the injured bronchoepithelial cells. In addition,
it can also be speculated that the detection of circulating
bronchoepithelial cells reflected lung cancer which had been
previously unproven clinically. At present, it is unclear
whether these circulating bronchoepithelial cells were
derived from the early lung cancer in pulmonary fibrosis
or only from damaged epithelial cells which migrated into
the capillary following lung injury. It can also be speculated
that these circulating bronchoepithelial cells were
480 K. DOHMOTO ET AL.premature stem cells derived from a relatively normal lung
to repair the injured epithelium quickly and eciently.
Future studies including follow up of the clinical course of
patients in whom SPA expressing bronchoepithelial cells
are detected will be required.
In conclusion, we demonstrate circulating broncho
epithelial cells expressing mRNA for SPA in patients with
pulmonary fibrosis (IPF and pulmonary fibrosis associated
with collagen vascular disorders). Circulating broncho
epithelial cells in pulmonary fibrosis may have played a
contributory role in the pathogenesis of IPF.
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